Aprea Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Aprea Therapeutics, Inc. carries a market capitalization of 6.70M, placing it among publicly traded companies globally. Its enterprise value stands at -31.29M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.70M |
| Enterprise Value | -31.29M |
Share Statistics
Aprea Therapeutics, Inc. currently has 12.39M shares outstanding.
| Shares Outstanding | 12.39M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.26 |
| P/TBV Ratio | 0.26 |
| P/FCF Ratio | -1.36 |
| P/OCF Ratio | -1.36 |
Financial Position
Aprea Therapeutics, Inc. maintains a current ratio of 13.55, meaning it holds 13.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 13.55 |
| Quick Ratio | 13.33 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -47.44 |
| Return on Assets (ROA) | -41.30 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Aprea Therapeutics, Inc.'s stock has declined approximately -67.73939% over the past 52 weeks. The 50-day moving average sits at 0.72, while the 200-day moving average is 0.77.
| Beta (5Y) | N/A |
| 52-Week Price Change | -67.73939% |
| 50-Day Moving Average | 0.72 |
| 200-Day Moving Average | 0.77 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -13.20M, while operating income came in at -13.22M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -13.22M |
| Pretax Income | -12.31M |
| Net Income | -12.31M |
| EBITDA | -13.20M |
| EBIT | -13.22M |
| Earnings Per Share (EPS) | -0.60 |
Balance Sheet
Total book value stands at 38.47M, with working capital of 38.82M providing operational flexibility.
| Cash & Cash Equivalents | 41.23M |
| Total Debt | N/A |
| Net Debt | -41.23M |
| Equity (Book Value) | 38.47M |
| Book Value Per Share | 3.10 |
| Working Capital | 38.82M |
Cash Flow
Aprea Therapeutics, Inc. produced -12.17M in operating cash flow over the past twelve months.
| Operating Cash Flow | -12.17M |
| Capital Expenditures | N/A |
| Free Cash Flow | -12.17M |
| FCF Per Share | -0.59 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -371.03 |
| FCF Yield | -73.78 |
Stock Splits
Aprea Therapeutics, Inc.'s most recent stock split took place on February 13, 2023 with a 20:1 split ratio.
| Last Split Date | 2/13/2023 |
| Split Ratio | 20:1 |
Scores
Aprea Therapeutics, Inc. posts an Altman Z-Score of -9.64, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -9.64 |